Actively Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
Led by Fujian Medical University · Updated on 2026-02-03
1296
Participants Needed
3
Research Sites
364 weeks
Total Duration
On this page
Sponsors
F
Fujian Medical University
Lead Sponsor
T
The First Affiliated Hospital of Dalian Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are: Does RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems? Is RIPC safe to use during emergency ATAAD surgery? Researchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery. Participants will: Receive either RIPC or a sham intervention during their surgery. Be monitored for up to 30 days after surgery for complications. Have follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.
CONDITIONS
Official Title
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any sex
- Diagnosis of acute Type A aortic dissection requiring emergency surgery with symptom onset less than 14 days
- Ability to understand study purpose, provide informed consent, and comply with follow-up
You will not qualify if you...
- Traumatic or iatrogenic aortic dissection
- Previous open cardiac or thoracic aortic surgery
- Severe preoperative organ dysfunction such as persistent deep coma, abdominal compartment syndrome, or circulatory failure
- Severe comorbidities including recent myocardial infarction within 7 days, recent stroke within 2 months, end-stage kidney or liver disease
- Evidence of ischemia or severe deformity in limb planned for intervention
- Peripheral arterial disease, Raynaud phenomenon, active phlebitis, or history of deep vein thrombosis in lower limbs
- Current use of sulfonylurea oral hypoglycemic agents or nicorandil
- Life expectancy less than 1 year due to conditions like advanced cancer
- Participation in another clinical trial without completion of its primary endpoint
- Pregnancy or lactation; immunodeficiency; known bleeding or coagulation disorders; active infection
- Other severe physical or psychiatric disorders or lab abnormalities that increase risk or interfere with study outcomes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
2
Xiamen Cardiovascular Hospital, Xiamen University
Xiamen, Fujian, China
Not Yet Recruiting
3
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Not Yet Recruiting
Research Team
L
Liang-wan Chen, M.D Ph.D
CONTACT
X
Xin-fan Lin, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here